First Announcement

2018 International Conference on the Natural Products and Traditional Medicine of the Belt and Road Initiatives

http://www.cnphars.org/2018Road/

May 6-10, 2018, Beijing, China

Invitation

Dear colleagues,

The 2018 International Conference on the Pharmacology of Traditional Medicine of the Belt and Road Initiatives, sponsored by Chinese Pharmacological Society (CNPHARS), will be held in Beijing, China on May 6-10, 2018.The theme of the conference is *Develop traditional medicines to benefit human health.*

The meeting will consist of plenary lectures, invited lectures, symposia, oral presentations, poster presentations and discussion sessions on the study of traditional medicines, which will offer a golden opportunity for all delegates and guests to communicate the ideas and suggestions, methods and technologies, research results, experience, etc. in pharmacological studies and drug R&D of traditional medicine pharmacology. In addition, exhibitions of drug and health product of traditional medicine will be held during the conference.

On behalf of the Organizing Committee, we look forward to welcoming pharmacologists from the countries and regions along the Belt and Road and also the interested pharmacologists all over the world to get-together in the ancient city Beijing. We believe that the conference will not only make a great contribution to enhancing communication and advancing practical cooperation with countries along the Belt and Road, but also to fostering regional and international communication and collaborations, and boost progress in the field of traditional medicine and new drug research.

We look forward to welcoming you in Beijing.

Co-chair

Professor Yong-Xiang Zhang

President of CNPHARS

Councilor of IUPHAR and

Chair of Natural Production of IUPHAR

Co-chair

Professor Guan-Hua Du

Former President of CNPHARS

Councilor of APFP

Main Topics

- pharmacodynamics, pharmacokinetics and the mechanisms of traditional medicine
- clinical pharmacology of traditional medicine
- research and development of drugs and health products based on traditional medicine
- new technology in traditional medicine research
- intellectual property protection and traditional medicine
- registration regulation and procedure for traditional medicine

Scientific Program

Date and Time		Program
May 6	9:00-21:00	Registration
May 7	9:00-9:30	Opening Ceremony
	9:30-12:00	Plenary Speeches
	14:00-17:30	Symposium 1: Pharmacokinetics, pharmacodynamics and mechanism of traditional medicine
May 8	9:00-12:00	Symposium 2: Clinical pharmacology of traditional medicine
	14:00-17:30	Symposium 3: Research and development of drugs and health products based on traditional medicine
May 9	9:00-12:00	Symposium 4: New technology application in traditional medicine
	14:00-15:30	Symposium 5: Intellectual property protection and traditional medicine
	15:30-17:00	Panel discussion: Registration regulation and procedure for traditional medicine
	17:00-17:30	Closing Ceremony
May 10	9:00-12:00	Departure

Time and Venue

Time: May 6th – 10th, 2018

Venue: Beijing Asia Hotel

Address: 8 West Xinzhong Street, Dongcheng District, Beijing 100027

Language

The official language of the conference is English. No translation services will be provided.

Call for abstracts

1. The deadline for the reception of abstracts will be **March 31st, 2018**. All accepted abstracts will be published on the special issue of *Chinese Journal of Pharmacology and Toxicology (CJPT)*.
2. The abstract includes the following information. **Templates** for original and review articles see the appendix to the Announcement.
   - **Title** must be informative, specific, and brief (not to exceed 30 words). No subtitle is permitted.
   - **Authors** should be the contributors who can answer the questions relevant to the articles. Full names of all authors, first name followed by the family name (family name in capital letters), should be given, for example, Guang-Hui YANG or Gang LI. The corresponding author needn't indicated by"*". Each registrant may be the presenting (first named) author of only one abstract, but may be a coauthor of multiple abstracts.
   - **Affiliations** and their full mailing addresses (countries or regions, province, city and postal code) should be listed beneath the authors. Affiliations should be in their full names, including the specific sections. If the authors are from different affiliations, numbers such as "1" and "2" should be inserted to the upper right corner of the authors' names in superscript as well as before the affiliations.
   - **Abstract** should be no more than 300 words or 1,500 printed symbols. Original article's abstracts should be written in a structured abstract format, indicating the OBJECTIVE, METHODS, RESULTS (key data should be presented instead of merely summarizing the main findings), and CONCLUSION. Non-structural abstracts are required in review articles. Use standard abbreviations for units of measure. Other abbreviations should be spelled out in full at the first mention, followed by the abbreviation in parentheses.
   - **Key words** (full names, not abbreviations) about three to five, separated by semicolons (;), should be listed after the abstract.

- **Footnotes** should be placed below the key words, including the source and the number of your fund, and the corresponding author, telephone number and E-mail address.

3. Please visit the website for this meeting (http://www.cnphars.org/2018Road/) to submit the abstract on line.
4. All the abstracts will be presented in poster format, except for those selected as oral presentations. The format of the poster is 120 cm high and 90 cm wide.

Excellent Presentation Selection

Poster presentation competition

Excellent poster presentations will be selected and awarded during the conference. The jury will select the awardees based on the content, expression, design and question answering. The members of the Executive Committee will constitute the jury. The awards will be presented during the closing ceremony of the conference. All poster presenters will be the awardee candidates.

Commercial Exhibition

The conference will welcome and offer excellent opportunities for medical and technology related enterprises to exhibit their equipment, products and achievements.

Contact person: Lei Yang

Email:yaolixuehui@163.com

Tel: +86 185 0017 7492

Hotel and Accommodation

Conference participants should contact directly the hotel of their interest. The following hotels are recommended:

1. **Beijing Asia Hotel**
   Address: 8 West Xinzhong St., Beijing, China (The same building of the conference venue)
   Negotiated price: RMB600 (single occupancy)/RMB700 (double occupancy) for Business Room 2.
2. **Swissotel Beijing★★★★★**
   Address: 2 Chaoyangmen North St., Beijing, China (About 5minutes walk to the Beijing Asia Hotel)
   Website: http://www.swisshotel-beijing.com/
3. **Poly Plaza Hotel★★★★**
   Address: 14 Dongzhimen South St., Beijing, China (About 7minutes walk to the Beijing

Asia Hotel)

Website: http://www.polyhotel.com/

4. **Oriental Garden Hotel★★★★**

Address: 6 South Dongzhimen St, Beijing, China (About 10minutes walk to the Beijing Asia Hotel)

Website: http://www.bjoghotel.com/

For other choices, please check the website: http://english.ctrip.com/

Registration Fee (USD)

Registration	Delegates	Students	note
Early registration Before March 31, 2018	$300	$200	
Registration After April 1, 2018	$400	$300	
Locus in quo	$500	$400	

Please visit the website for this meeting (http://www.cnphars.org/2018Road/) to register on line. The deadline for early registration is **March 31, 2018**. The online registration will open from December 15**,** 2017.

Location Information

Contact Secretariat

Dr. Ying Zhao, E-mail: zhaoying@imm.ac.cn; cnphars@163.com

Tel/Fax: +86 10 63165211

Mobile: +86 138 1031 7891

Address: 1 Xian Nong Tan, Xicheng District, Beijing 100050, China

Appendix: Templates for original and review articles

Abstract format to Chinese Journal of Pharmacology and Toxicology

1. **Title** must be informative, specific, and brief (not to exceed 30 words). No subtitle is permitted.
2. **Authors** should be the contributors who can answer the questions relevant to the articles. Full names of all authors, **first name followed by the family name (family name in capital letters)**, should be given, for example, Guang-Hui YANG or Gang LI. The corresponding author needn't indicated by "*".
3. **Affiliations** and their full mailing addresses (countries or regions, province, city and postal code) should be listed beneath the authors. Affiliations should be in their full names, including the specific sections. If the authors are from different affiliations, numbers such as "1" and "2" should be inserted to the upper right corner of the authors' names in superscript as well as before the affiliations.
4. **Abstracts** should be no more than 300 words or 1,500 printed symbols. Original article's abstracts should be written in a structured abstract format, indicating the OBJECTIVE, METHODS, RESULTS (key data should be presented instead of merely summarizing the main findings), and CONCLUSION. **Non-structural abstracts are required in review articles.** The abbreviations first appeared in the abstract should be typed with their full words.
5. **Key words** (full names, not abbreviations) about three to five, separated by semicolons (;), should be listed after the abstract.
6. **Footnotes** should be placed below the key words, including the source and the number of your fund, and the corresponding author, telephone number and E-mail address.
7. The more details can be found in **Website**: http:/ /www.cjpt.ac.cn:81.

TEMPLATE FOR ORIGINAL ARTICALS:

Effect and mechanism of baicalein on 2,4,6-trinitrobenzene sulfonic acid-induced experimental colitis of mice

Xiao-ping LUO[1], Zhi-lun YU[2], Chao DENG[1], Jing-jing ZHANG[2], Zheng-tao WANG[2], Wei DOU[1,2]

(1.Ministry of Education Key Laboratory for Standardization of Chinese Medicine , 2.Shanghai Key Laboratory of Complex Prescriptions, Institute of Chinese Materia Medica, Shanghai University of TCM, Shanghai 201203, China)

Abstract: OBJECTIVE To explore the effect and mechanisms of baicalein on 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced experimental colitis in mice. METHODS BALB/c mice were randomly placed into three groups (*n*=10): normal control group, TNBS group, and TNBS+baicalein (20 mg·kg^{-1}, once per day) group. Mouse colitis was induced by intrarectal injection of TNBS. Baicalein was administered by oral gavage two days prior to TNBS treatment and until the end of the study (a total of 9 d). The colon length was measured before HE staining was performed for histological damage assessment. The remaining colon pieces were collected to measure the content of tumor necrosis factor-α (TNF-α). Lipopolysaccharides (LPS)-stimulated RAW264.7 mouse macrophage was used as a cell model to determine the content of nitric oxide (NO) in cell culture medium, the mRNA levels of TNF-α, interleukin-6 (IL-6), IL-1β, inducible nitric oxide synthase (iNOS), cyclooxygenase 2 (COX- 2) and monocyte chemoattractant protein-1 (MCP-1), and the protein expression of phosphatidylinositol 3- kinase/protein kinase B/nuclear factor-κB (PI3K/AKT/NF-κB) pathway. RESULTS Baicalein significantly attenuated TNBS-induced colon shortening and histological injury (P<0.05), which was correlated with the decline in the content of TNF-α in the colon tissue. According to the *in vivo* results, baicalein exposure down-regulated the secretion of NO and the mRNA expression of pro-inflammatory mediators (iNOS, COX-2, MCP-1, TNF-α, IL-1β and IL-6) in LPS-stimulated RAW264.7 cells (P<0.05, P<0.01). Additionally, the phosphorylation/activation of LPS- stimulated PI3K/AKT/NF-κB pathway was inhibited by baicalein treatment. CONCLUSION The beneficial effect of baicalein in TNBS-induced experimental colitis may be due to PI3K/AKT/NF-κB signaling inhibition.

Key words: colitis; phosphatidylinositol 3-kinase; protein kinase B; NF-κB; baicalein

Foundation item: The project supported by National Natural Science Foundation of China (81273572; 81530069)

Corresponding author: Wei DOU, E-mail:douwei123456@126.com, Tel:(021) 51322498

TEMPLATE FOR REVIEW ARTICLES:

Rational design of G protein-coupled receptor kinases 2 inhibitors for treatment of heart failure

John J TESMER[1,2], Helen V WALDSCHMIDT[1], Marie C CATO, Renee BOULEY [1], Osvaldo CRUZ-RODRIGUEZ [1], Scott D LARSEN[3]

(1. Life Sciences Institute, 3. Valteich Medicinal Chemistry Core, University of Michigan, Ann Arbor Michigan USA, 48109; 2. Department of Biological Sciences, Purdue University, West Lafayette Indiana USA,47907)

Abstract： G protein-coupled receptors (GPCRs) convert extracellular stimuli in the form of hormones, odorants and light into profound changes in cell homeostasis. Their timely desensitization is critical for cells to rapidly respond to changes in their environment and to avoid damage from sustained signaling. Seven GPCRs kinases (GRKs) phosphorylate and regulate the activity of most of the ~800 GPCRs in the human genome. Although GRKs normally play an adaptive role, in conditions such as chronic heart failure they are overexpressed and linked to disease progression. GRK2 and GRK5 have thus become important targets for the treatment of heart failure and pathological cardiac hypertrophy, respectively. Our lab has determined atomic structures representing all three vertebrate GRK subfamilies, and is now in the midst of a campaign to develop selective inhibitors of these enzymes using structure-based rational design. We have identified the FDA approved drug paroxetine as a selective GRK2 inhibitor, determined the crystal structure of the GRK2·paroxetine complex and, in collaboration with the Koch lab, showed that the drug improves contractility in myocytes and, most impressively, recovery in post-myocardial infarcted mice. Since then, we have identified additional chemical scaffolds that exhibit even higher potency and/or selectivity for GRK5. Using a “hybrid” inhibitor design approach we have generated GRK selective chemical probes that exhibit improved potency and stability and are able to increase inotropy and dampen the hypertrophic response in cardiomyocytes and small animal models. Structural analysis has revealed the molecular basis for selectivity and potency in many of these compounds, allowing for the design of future generations of GRK chemical probes.

Key words: heart failure; G protein-coupled receptors; paroxetine; drug design; X-ray crystallography

Foundation item: The project was supported by National Institutes of Health grants (HL071818; HL086865; and HL122416); American Heart Association grant (15PRE22730028); and the University of Michigan Chemistry Biology Interface training program (NIH grant 5T32GM008597).

Corresponding author: John J TESMER, E-mail: jtesmer@purdue.edu, Tel: 1 765-494-1807